disease

Tauopathy

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Tauopathy: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1580Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

Summary

Tauopathy is a disease characterized by neurodegeneration research. Key relationships include: activates, associated with, inhibits. Associated with Aging, Als, Alzheimer. Connected to 368 entities in the SciDEX knowledge graph.

View on Wiki →

Disease Info

Morphology	pyramidal neuron (source: Cell Ontology)
Associated Genes	CGAS, TREM2, APOE, APOE4, ABCA1, JUN, CHMP6, RAB35
KG Connections	647 knowledge graph edges
Databases	OMIM Orphanet ClinicalTrials PubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    Tauopathy["Tauopathy"] -->|"activates"| Cholesterol["Cholesterol"]
    Tauopathy["Tauopathy"] -->|"therapeutic target"| Lipid_Metabolism["Lipid Metabolism"]
    Tauopathy["Tauopathy"] -->|"activates"| Autophagy["Autophagy"]
    Tauopathy["Tauopathy"] -->|"activates"| Phagocytosis["Phagocytosis"]
    Tauopathy["Tauopathy"] -.->|"inhibits"| Nf__b["Nf-Kappab"]
    Tauopathy["Tauopathy"] -->|"therapeutic target"| Apoptosis["Apoptosis"]
    JUN["JUN"] -->|"therapeutic target"| Tauopathy["Tauopathy"]
    APOE["APOE"] -->|"activates"| Tauopathy["Tauopathy"]
    ABCA1["ABCA1"] -->|"therapeutic target"| Tauopathy["Tauopathy"]
    RAB7A["RAB7A"] -->|"activates"| Tauopathy["Tauopathy"]
    style Tauopathy fill:#ef5350,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (668)

Target	Relation	Type	Str
Alzheimer	associated_with	disease	1.00
Neurodegeneration	associated_with	disease	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
Autophagy	activates	pathway	1.00
Neurodegeneration	contributes_to	process	0.90
Microtubule	causes	protein	0.85
Senescent Microglia	associated_with	cell_type	0.80
Als	activates	disease	0.75
Alzheimer	therapeutic_target	disease	0.75
Inflammation	activates	disease	0.75
Cholesterol	activates	pathway	0.70
Apoptosis	therapeutic_target	pathway	0.70
Stem Cell	activates	pathway	0.70
Mtor	activates	pathway	0.70
Autophagy	interacts_with	pathway	0.70
Alzheimer	causes	disease	0.65
Huntington	activates	disease	0.65
Neurodegeneration	inhibits	disease	0.65
Als	therapeutic_target	disease	0.65
Neuroinflammation	activates	disease	0.65
Neurodegeneration	regulates	disease	0.65
Neuroinflammation	regulates	disease	0.65
Inflammation	regulates	disease	0.65
Alzheimer	regulates	disease	0.65
Alzheimer	inhibits	disease	0.65
Neuroinflammation	treats	disease	0.65
Inflammation	treats	disease	0.65
Alzheimer	treats	disease	0.65
Lipid Metabolism	therapeutic_target	pathway	0.60
Phagocytosis	activates	pathway	0.60
Nf-Κb	inhibits	pathway	0.60
Mtor	inhibits	pathway	0.60
Autophagy	inhibits	pathway	0.60
Calcium Signaling	therapeutic_target	pathway	0.60
Mitophagy	therapeutic_target	pathway	0.60
Immunotherapy	associated_with	pathway	0.60
Microbiota	expressed_in	pathway	0.60
Rna Splicing	inhibits	pathway	0.60
Complement	activates	pathway	0.60
Senescence	activates	pathway	0.60
Immune Response	activates	pathway	0.60
Blood-Brain Barrier	treats	pathway	0.60
Nf-Kb	inhibits	pathway	0.60
Oxidative Stress	treats	pathway	0.60
Mapk	treats	pathway	0.60
Synaptic Plasticity	treats	pathway	0.60
Endocytosis	interacts_with	pathway	0.60
Differentiation	interacts_with	pathway	0.60
Oxidative Stress	interacts_with	pathway	0.60

Incoming (912)

Source	Relation	Type	Str
MICROGLIA	activates	gene	1.00
NEURODEGENERATIVE DISEASES	activates	gene	1.00
ALZHEIMER'S DISEASE	activates	gene	1.00
NEURODEGENERATION	activates	gene	1.00
TAU	activates	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
ALZHEIMER'S DISEASE	associated_with	gene	1.00
TAU	associated_with	gene	1.00
ALZHEIMER	activates	gene	1.00
TAUOPATHY	activates	gene	1.00
AMYLOID	activates	gene	1.00
TAUOPATHY	associated_with	gene	1.00
ALZHEIMER	associated_with	gene	1.00
AUTOPHAGY	activates	gene	0.95
TAUOPATHY	expressed_in	gene	0.95
TAU	biomarker_for	protein	0.95
MAPT	causes	gene	0.95
Lipid Droplet Accumulation	associated_with	phenotype	0.90
TRIAD3A	protects_against	protein	0.90
Ps19 Mouse Model	associated_with	disease	0.90
9H6F2 Antibody	biomarker_for	biomarker	0.88
Als	associated_with	disease	0.85
ALZHEIMER'S DISEASE	inhibits	gene	0.85
TAU PATHOLOGY	therapeutic_target	gene	0.85
TAU	inhibits	gene	0.85
NEURODEGENERATION	regulates	gene	0.85
TAU	regulates	gene	0.85
TAUOPATHY	inhibits	gene	0.85
TYROBP Deficiency	protects_against	phenotype	0.85
TAU	therapeutic_target	gene	0.85
TAUOPATHY	therapeutic_target	gene	0.85
ALZHEIMER	therapeutic_target	gene	0.85
ALZHEIMER'S DISEASE	therapeutic_target	gene	0.85
TAUOPATHY	regulates	gene	0.85
MICROGLIA	regulates	gene	0.85
Tau Inclusions	biomarker_for	phenotype	0.85
Neuroinflammation	interacts_with	process	0.85
APP E590D	exacerbates	protein	0.85
Autophagic Body Accumulation	associated_with	phenotype	0.80
Auto-AMPH1 Antibodies	biomarker_for	biomarker	0.80
APOE	associated_with	gene	0.75
APOE4	activates	gene	0.75
APOE4	associated_with	gene	0.75
CGAS	activates	gene	0.75
APOE3	activates	gene	0.75
TREM2	activates	gene	0.75
CCL5	activates	gene	0.75
CCR5	activates	gene	0.75
NEURODEGENERATION	inhibits	gene	0.75
CYTOKINES	activates	gene	0.75

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinf	0.444	Alzheimer's disease	TREM2 agonism vs antagonism in DAM micro

Mentioning Analyses (2)

Scientific analyses that reference this entity

Why does PRKN-mediated mitophagy, typically protective, cause harmful mitochondr

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.455

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

neurodegeneration | 2026-04-15 | 0 hypotheses

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
The gain-of-function TREM2-T96K mutation increases risk for Alzheimer's disease [PMID:41109213]	Pilat DJ, Le H, Prokopenko D, Lin CJ, Ei	Neuron	2026
Role of TREM2 in neuroinflammation. [PMID:41213496]	Abdulkhaliq AA, Alasiri G, Almoghrabi Y,	Exp Neurol	2026
Synergistic potential of TREM2 agonists and exercise training in Alzheimer's dis [PMID:41494649]	Zhang J, St Pierre Schneider B, Muguerza	Am J Physiol Endocrinol Metab	2026
Diankuang Mengxing Decoction exerts neuroprotective effects in post-stroke depre [PMID:41534750]	Yang X, Zhao Y, Liu W, Feng J, Wu X et a	J Ethnopharmacol	2026
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvir [PMID:41576929]	Mateus-Tique J, Lakshmi A, Singh B, Iyer	Cancer Cell	2026
Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952]	Li X, Tang X, Zeng J, Duan L, Hou Z et a	Cell	2026
TREM2 expression level is critical for microglial state, metabolic capacity and [PMID:41580393]	Feiten AF, Dahm K, Schlepckow K, van Len	Nat Commun	2026
Large-scale single-cell analysis and in silico perturbation reveal dynamic evolu [PMID:41617928]	Xia P, Shuang S, Fu D, Liu L, Yang D et	NPJ Precis Oncol	2026
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant [PMID:41720086]	Zhao Q, Huang R, Wang C, Hu J, Nie R et	Cancer Cell	2026
TREM2 deficiency delays postnatal microglial maturation and synaptic pruning, le [PMID:41930604]	Yang HC, Deng YS, Zhang J, Zhang T, Song	J Alzheimers Dis	2026
Hierarchical Targeting of TREM2(+) Myeloid Cells via Acid-Triggered OMVs Reprogr [PMID:41945876]	Chen F, Xue Y, Ma X, Chen L, Shao Z et a	Adv Sci (Weinh)	2026
Correction to "A Strategy Involving Microporous Microneedles Integrated with CAR [PMID:41952643]	Unknown	Advanced materials (Deerfield	2026
TREM2 in neurodegeneration and diseases. [PMID:41792456]	["Abdulkhaliq A", "Alasiri G", "Kim B",	Molecular psychiatry	2026
Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721]	Aranda-Abreu GE, Rojas-Durán F, Hernánde	Neurology international	2026
Molecular mechanism of Alzheimer's disease using integrated multi-omics. [PMID:41907842]	Alhusaini M, Mussa BM, Ilce BY, Alhaj H,	Frontiers in aging neuroscienc	2026
Viral and non-viral cellular therapies for neurodegeneration. [PMID:41585268]	["Srivastav Jyotsna", "Sharma Sachin"]	Frontiers in medicine	2025
Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy. [PMID:20301376]	Adam MP, Bick S, Mirzaa GM, Pagon RA, Wa		1993

Tauopathy

Understanding Entity Pages

Summary

Wiki Pages (21)

Hippocampal CA1 Pyramidal Neurons in Aging-Related Tauopathy

cbs-psp-daily-action-plan

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Clinical Management Guide for CBS/PSP

Progressive Supranuclear Palsy (PSP)

Corticobasal Syndrome (CBS)

Novel Therapy Index

primary-progressive-aphasia

CBS/PSP Supplements Guide

Atypical Parkinsonism

Device Therapies Comparison for CBS/PSP

CBS/PSP Rehabilitation Master Guide

calcium-dysregulation-comparison

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Myoclonus and Cortical Hyperexcitability in Corticobasal Syndrome

Alzheimer's Disease Mechanism Index

Corticobasal Degeneration (CBD)

Therapeutics

PI-2620 Tau PET in PSP

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Frontotemporal Dementia (FTD) Mechanistic Pathway